Cetera Investment Advisers
PYXS icon

Cetera Investment Advisers’s Pyxis Oncology PYXS Stock Holding History

Cetera Investment Advisers’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.8K Hold
27,260
– – ﹤0.01% 4605
2025
Q4 		$31.3K Sell
27,260
-500
-2% -$1.76K ﹤0.01% 4555
2025
Q3 		$61.6K Sell
27,760
-1,000
-3% -$1.44K ﹤0.01% 4405
2025
Q2 		$31.6K Buy
28,760
+900
+3% +$1.01K ﹤0.01% 4001
2025
Q1 		$27.3K Buy
27,860
+1,000
+4% +$1.33K ﹤0.01% 3897
2024
Q4 		$41.9K Buy
26,860
+1,000
+4% +$2.88K ﹤0.01% 3665
2024
Q3 		$94.9K Sell
25,860
-2,250
-8% -$7.87K ﹤0.01% 3546
2024
Q2 		$93K Sell
28,110
-1,250
-4% -$5.25K ﹤0.01% 3522
2024
Q1 		$125K Buy
29,360
+8,998
+44% +$37.8K ﹤0.01% 3455
2023
Q4 		$36.7K Buy
20,362
+1,102
+6% +$1.89K ﹤0.01% 2178
2023
Q3 		$38.3K Buy
19,260
+1,000
+5% +$2.32K ﹤0.01% 2138
2023
Q2 		$46.7K Buy
+18,260
New +$57.9K ﹤0.01% 2126

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Investment Advisers's PYXS Position: Q1 2026 in Review

Cetera Investment Advisers held its Pyxis Oncology (PYXS) position steady in Q1 2026 at 27,260 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4605.

Cetera Investment Advisers first reported a position in PYXS in Q2 2023 and has held it in 12 quarters since. The position peaked at $125K in Q1 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Cetera Investment Advisers held 27,260 shares of Pyxis Oncology worth $39.8K as of Q1 2026.
  • Cetera Investment Advisers left its Pyxis Oncology share count unchanged in Q1 2026.
  • Pyxis Oncology made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #4605 holding.
  • Cetera Investment Advisers first reported a position in Pyxis Oncology in Q2 2023 and has held it in 12 quarters since.
  • Cetera Investment Advisers's Pyxis Oncology position peaked at $125K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.